KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Cost of Revenue (2016 - 2026)

Bio-Rad Laboratories has reported Cost of Revenue over the past 18 years, most recently at $282.7 million for Q1 2026.

  • Quarterly Cost of Revenue rose 1.18% to $282.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Mar 2026, up 5.45% year-over-year, with the annual reading at $1.2 billion for FY2025, 4.69% up from the prior year.
  • Cost of Revenue was $282.7 million for Q1 2026 at Bio-Rad Laboratories, down from $348.0 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $348.0 million in Q4 2025 and troughed at $279.4 million in Q1 2025.
  • The 5-year median for Cost of Revenue is $306.3 million (2025), against an average of $305.5 million.
  • Year-over-year, Cost of Revenue fell 11.06% in 2024 and then rose 8.08% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $333.2 million in 2022, then decreased by 5.51% to $314.8 million in 2023, then increased by 3.43% to $325.6 million in 2024, then increased by 6.88% to $348.0 million in 2025, then dropped by 18.76% to $282.7 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Cost of Revenue are $282.7 million (Q1 2026), $348.0 million (Q4 2025), and $309.6 million (Q3 2025).